Unii-4bmh7izt98
|
|
|
- CAS-Nr.
- 856676-23-8
- Englisch Name:
- Unii-4bmh7izt98
- Synonyma:
- Choline Fenofibrate;Trilipix;Abt 335;Unii-4bmh7izt98;Fenofibrate de choline;Unii-4bmh7izt98 USP/EP/BP;Unii-4bmh7izt98 856676-23-8;Fenofibric acid choline salt;Choline Fenofibrate (CFRC-3);Choline fenofibrate (ABT-335)
- CBNumber:
- CB62494614
- Summenformel:
- C22H28ClNO5
- Molgewicht:
- 421.91442
- MOL-Datei:
- 856676-23-8.mol
|
Unii-4bmh7izt98 Eigenschaften
- Schmelzpunkt:
- 210-212°C
- storage temp.
- Hygroscopic, -20°C Freezer, Under Inert Atmosphere
- Löslichkeit
- Methanol (Slightly), Water (Slightly)
- Aggregatzustand
- Solid
- Farbe
- White to Off-White
- Stabilität:
- Hygroscopic
Sicherheit
- Risiko- und Sicherheitserklärung
- Gefahreninformationscode (GHS)
| Bildanzeige (GHS) |
|
| Alarmwort |
Warnung |
| Gefahrenhinweise |
| Code |
Gefahrenhinweise |
Gefahrenklasse |
Abteilung |
Alarmwort |
Symbol |
P-Code |
| H302 |
Gesundheitsschädlich bei Verschlucken. |
Akute Toxizität oral |
Kategorie 4 |
Warnung |
![GHS hazard pictograms]() src="/GHS07.jpg" width="20" height="20" /> |
P264, P270, P301+P312, P330, P501 |
| H315 |
Verursacht Hautreizungen. |
Hautreizung |
Kategorie 2 |
Warnung |
![GHS hazard pictograms]() src="/GHS07.jpg" width="20" height="20" /> |
P264, P280, P302+P352, P321,P332+P313, P362 |
| H319 |
Verursacht schwere Augenreizung. |
Schwere Augenreizung |
Kategorie 2 |
Warnung |
![GHS hazard pictograms]() src="/GHS07.jpg" width="20" height="20" /> |
P264, P280, P305+P351+P338,P337+P313P |
| H332 |
Gesundheitsschädlich bei Einatmen. |
Akute Toxizität inhalativ |
Kategorie 4 |
Warnung |
![GHS hazard pictograms]() src="/GHS07.jpg" width="20" height="20" /> |
P261, P271, P304+P340, P312 |
| H335 |
Kann die Atemwege reizen. |
Spezifische Zielorgan-Toxizität (einmalige Exposition) |
Kategorie 3 (Atemwegsreizung) |
Warnung |
![GHS hazard pictograms]() src="/GHS07.jpg" width="20" height="20" /> |
|
|
| Sicherheit |
| P261 |
Einatmen von Staub vermeiden. |
| P280 |
Schutzhandschuhe/Schutzkleidung/Augenschutz tragen. |
| P305+P351+P338 |
BEI KONTAKT MIT DEN AUGEN: Einige Minuten lang behutsam mit Wasser spülen. Eventuell vorhandene Kontaktlinsen nach Möglichkeit entfernen. Weiter spülen. |
|
Unii-4bmh7izt98 Chemische Eigenschaften,Einsatz,Produktion Methoden
Beschreibung
Choline fenofibrate, a salt formulation of fenofibric acid, is a lipid
regulating agent available as delayed release capsules for oral administration. It is indicated in combination with a statin to reduce TG and
increase high-density lipoprotein cholesterol (HDL-C) in patients with
mixed dyslipidemia and coronary heart disease (CHD) or a CHD-risk
equivalent who are optimal for statin therapy to achieve their lowdensity lipoprotein cholesterol (LDL-C) goal. In addition, choline
fenofibrate is indicated as monotherapy in patients with severe
hypertriglyceridemia to reduce TG, and in patients with primary
hyperlipidemia or mixed dyslipidemia to reduce elevated LDL-C, total
cholesterol, TG, apolipoprotein B, and to increase HDL-C. Fenofibric acid
is also the active metabolite of fenofibrate (Tricor), which has been
previously marketed for the treatment of hypercholesterolemia and
hypertriglyceridemia.
The primary mode of action of fenofibric acid
is through the activation of the nuclear transcription factor PPARa,
predominantly expressed in tissues that metabolize fatty acids, such as
the liver, kidney, heart, and muscle.
On activation by binding of the fibrate, PPARa binds as heterodimers with retinoid X receptor (RXR), which subsequently recognizes and binds to specific PPARa-response elements leading to modulation of expression of the target genes. In particular, the activity of lipoprotein lipase is increased and synthesis of apoprotein C-III is decreased, which together enhance the clearance of circulating TG-rich lipoproteins. The resulting fall in TG produces an alteration in the size and composition of LDL from small dense particles to large buoyant particles. These larger particles have a greater affinity for cholesterol receptors and are catabolized rapidly. Choline fenofibriate acid is contraindicated in patients with severe renal impairment.
Chemische Eigenschaften
White Solid
Nebenwirkungen
The most common adverse reactions observed with the use of fenofibric acid alone or in combination with a statin are headache, back pain, nasopharyngitis, nausea, myalgia, diarrhea, and upper respiratory tract infection.
Unii-4bmh7izt98 Upstream-Materialien And Downstream Produkte
Upstream-Materialien
Downstream Produkte
Unii-4bmh7izt98 Anbieter Lieferant Produzent Hersteller Vertrieb Händler.
Global( 136)Lieferanten
856676-23-8()Verwandte Suche:
- Abt 335
- Fenofibrate de choline
- Unii-4bmh7izt98
- 2-Hydroxy-N,N,N-triMethylethanaMiniuM 2-[4-(4-chlorobenzoyl)phenoxy]
-2-Methylpropanoate
- 2-hydroxy-N,N,N-trimethyl, 2-{4-(4-chlorobenzoyl)phenoxy]-2-methylpropanoate
- Fenofibrate Impurity 8(Choline Fenofibrate)
- 2-Hydroxy-N,N,N-trimethylethan-1-aminium 2-(4-(4-chlorobenzoyl)phenoxy)-2-methylpropanoate
- 2-[4-(4-chlorobenzoyl)phenoxy]-2-methylpropanoate,2-hydroxyethyl(trimethyl)azanium
- Choline Fenofibrate (CFRC-3)
- Fenofibric acid choline salt
- Unii-4bmh7izt98 USP/EP/BP
- Fenofibric acid choline saltQ: What is
Fenofibric acid choline salt Q: What is the CAS Number of
Fenofibric acid choline salt Q: What is the storage condition of
Fenofibric acid choline salt Q: What are the applications of
Fenofibric acid choline salt
- Unii-4bmh7izt98 856676-23-8
- Trilipix
- Choline Fenofibrate
- tert-butylN-(1-amino-2-oxoazetidin-7-yl)carbamate
- Choline fenofibrate (ABT-335)
- 856676-23-8
- C22H28ClNO5
- API
- Aromatics
- Intermediates & Fine Chemicals
- Pharmaceuticals
